Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors

被引：0
|
作者：
Tinghu Zhang
Nicholas Kwiatkowski
Calla M Olson
Sarah E Dixon-Clarke
Brian J Abraham
Ann K Greifenberg
Scott B Ficarro
Jonathan M Elkins
Yanke Liang
Nancy M Hannett
Theresa Manz
Mingfeng Hao
Bartlomiej Bartkowiak
Arno L Greenleaf
Jarrod A Marto
Matthias Geyer
Alex N Bullock
Richard A Young
Nathanael S Gray
机构：
[1] Dana–Farber Cancer Institute,Department of Cancer Biology
[2] Harvard Medical School,Department of Biological Chemistry and Molecular Pharmacology
[3] Whitehead Institute for Biomedical Research,Department of Structural Immunology
[4] Structural Genomics Consortium,Department of Pharmacy
[5] University of Oxford,Department of Biochemistry
[6] Institute of Innate Immunity,Department of Biology
[7] University of Bonn,undefined
[8] Center of Advanced European Studies and Research,undefined
[9] Bonn,undefined
[10] Blais Proteomics Center,undefined
[11] Dana–Farber Cancer Institute,undefined
[12] Pharmaceutical and Medicinal Chemistry,undefined
[13] Saarland University,undefined
[14] Duke University Medical Center,undefined
[15] Massachusetts Institute of Technology,undefined
来源：
Nature Chemical Biology | 2016年 / 12卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
A small molecule inhibits CDK12 and CDK13 activity through covalent modification of Cys residues and reveals a role of the two kinases in regulating Pol II processivity and super-enhancer-driven transcription factor and DNA damage response gene expression.[graphic not available: see fulltext]
引用
收藏
页码：876 / 884
页数：8
相关论文
共 50 条
  • [41] Targeting CDK12 for Cancer Therapy: Function, Mechanism, and Drug Discovery
    Liu, Hui
    Liu, Kangdong
    Dong, Zigang
    CANCER RESEARCH, 2021, 81 (01) : 18 - 26
  • [42] Structure-Based Design of Selective Noncovalent CDK12 Inhibitors
    Johannes, Jeffrey W.
    Denz, Christopher R.
    Su, Nancy
    Wu, Allan
    Impastato, Anna C.
    Mlynarski, Scott
    Varnes, Jeffrey G.
    Prince, D. Bryan
    Cidado, Justin
    Gao, Ning
    Haddrick, Malcolm
    Jones, Natalie H.
    Li, Shaobin
    Li, Xiuwei
    Liu, Yang
    Nguyen, Toan B.
    O'Connell, Nichole
    Rivers, Emma
    Robbins, Daniel W.
    Tomlinson, Ronald
    Yao, Tieguang
    Zhu, Xiahui
    Ferguson, Andrew D.
    Lamb, Michelle L.
    Manchester, John I.
    Guichard, Sylvie
    CHEMMEDCHEM, 2018, 13 (03) : 231 - 235
  • [43] Therapeutic potential of dual CDK12 and 13 inhibition in colorectal cancer
    Altunel, Erdem
    Zokaasadi, Mohammad
    Somarelli, Jason A.
    McCall, Shannon J.
    Gultawatvichai, Patan
    Whalen, Giles Francis
    Pitarresi, Jason
    Hsu, David S.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [44] A selective Cdk12/13 non-covalent inhibitor with potent anti-breast cancer activity
    Quereda, V.
    Bayle, S.
    Francesca, V.
    Andrii, M.
    William, R.
    Derek, D.
    CANCER RESEARCH, 2019, 79 (04)
  • [45] The promise and current status of CDK12/13 inhibition for the treatment of cancer
    Tadesse, Solomon
    Duckett, Derek R.
    Monastyrskyi, Andrii
    FUTURE MEDICINAL CHEMISTRY, 2021, 13 (02) : 117 - 141
  • [46] Noncovalent CDK12/13 dual inhibitors-based PROTACs degrade CDK12-Cyclin K complex and induce synthetic lethality with PARP inhibitor
    Niu, Tian
    Li, Kailin
    Jiang, Li
    Zhou, Zhesheng
    Hong, Ju
    Chen, Xuankun
    Dong, Xiaowu
    He, Qiaojun
    Cao, Ji
    Yang, Bo
    Zhu, Cheng-Liang
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2022, 228
  • [47] Targeting cdk12/13 re-sensitizes trastuzumab resistant her2+breast cancers
    Vena, Francesca
    Aceti, Max
    Bayle, Simon
    Quereda, Victor
    Monastyrskyi, Andrii
    Roush, William
    Duckett, Derek
    CANCER RESEARCH, 2019, 79 (13)
  • [48] Targeting chemoresistant ovarian malignancies to cytostatic drugs and PARP inhibitors by inhibition of CDK12 kinase activity.
    Kohoutek, Jiri
    Svoboda, Marek
    Vrabel, David
    Paculova, Hana
    Dzimkova, Marta
    CLINICAL CANCER RESEARCH, 2016, 22
  • [49] Preclinical evaluation of PD and efficacy of novel potent selective and orally bioavailable CDK12 covalent inhibitors in TNBC model
    Poddutoori, Ramulu
    Rajagopalan, Sujatha
    Mukherjee, Subhendu
    Marappan, Sivapriya
    Samiulla, D. S.
    Sivakumar, Sasirekha
    Nayak, Shilpa S.
    Ravindra, M., V
    Murtuza, Hadianawala
    Devaraja, T. S.
    Kondela, Srinivas
    Tgore, Suraj
    Dhudashiya, Amit A.
    Charamanna, K. B.
    Antony, Thomas
    Daginakatte, Girish
    Giri, Sanjeev
    Chelur, Shekar
    Ramachandra, Murali
    Pandit, Chetan
    Samajdar, Susanta
    CANCER RESEARCH, 2018, 78 (13)
  • [50] Discovery and evaluation of ISM6466A, a novel covalent CDK12 inhibitor for the treatment of cancer
    Min, Lihua
    Lu, Hongfu
    Zhang, Yihong
    Wu, Jianping
    Cai, Xin
    Zheng, Min
    Cui, Hui
    Qiao, Junwen
    Ding, Xiao
    Rao, Sujata
    Ren, Feng
    Zhavoronkov, Alex
    CANCER RESEARCH, 2023, 83 (07)
12345